2000
Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Bensen W, Zhao S, Burke T, Zabinski R, Makuch R, Maurath C, Agrawal N, Geis G. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. The Journal Of Rheumatology 2000, 27: 1876-83. PMID: 10955327.Peer-Reviewed Original ResearchMeSH KeywordsAbdominal PainAnti-Inflammatory Agents, Non-SteroidalArthritis, RheumatoidCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDigestive SystemDouble-Blind MethodDyspepsiaFemaleHumansIsoenzymesMaleMembrane ProteinsMiddle AgedNaproxenNauseaOsteoarthritisProspective StudiesProstaglandin-Endoperoxide SynthasesPyrazolesRisk FactorsSulfonamidesTime FactorsTreatment OutcomeConceptsUpper gastrointestinal tolerabilityUpper GI symptomsSevere abdominal painComposite endpointAbdominal painGastrointestinal tolerabilityGI symptomsIndependent predictorsRheumatoid arthritisRelative riskCOX-2-specific inhibitorsUpper GI tolerabilityTreatment group patientsDose-response relationshipGI tolerabilityPlacebo patientsGroup patientsCumulative incidenceParallel groupClinical trialsPlaceboPatientsCelecoxibTolerabilityEndpoint
1979
cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer.
Young R, Von Hoff D, Gormley P, Makuch R, Cassidy J, Howser D, Bull J. cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer. Journal Of The National Cancer Institute 1979, 63: 1539-44. PMID: 387224.Peer-Reviewed Original ResearchConceptsCombination chemotherapy studiesAdvanced ovarian cancerSingle-agent activityOverall response rateLife-table analysisOvarian Cancer StudyEvaluable patientsForced diuresisSubstantial nauseaHematologic toxicityChemotherapy studiesRenal toxicityOvarian adenocarcinomaOvarian cancerResponse ratePatientsCancer studiesTreatmentToxicityNauseaVomitingDiuresisAdenocarcinomaMajor roleTherapy